Kidswell Bio

Kidswell Bio EBITDA per Employee

The EBITDA per Employee of Kidswell Bio (4584.T) as of Oct 29, 2026 is -8.75 M JPY. In the previous year, EBITDA per Employee was 2.84 M JPY — a change of -408.55% (lower).

EBITDA per Employee

-8.75 MJPY

YoY

-408.55%

Last updated:

EBITDA per Employee of Kidswell Bio is 2026 -8.75 M JPY. EBITDA per Employee of Kidswell Bio was 2025 2.84 M JPY. It decreases by -408.55% lower compared to the previous year.

The Kidswell Bio EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
-19.62 M JPY
Jan 1, 2020
-178.27 M JPY
Jan 1, 2021
-23.89 M JPY
Jan 1, 2022
-15.88 M JPY
Jan 1, 2023
-15.09 M JPY
Jan 1, 2024
-33.63 M JPY
Jan 1, 2025
2.84 M JPY
Jan 1, 2026
-8.75 M JPY
The Kidswell Bio EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-8.75 MJPY-408.55%
2.84 MJPY-108.43%
-33.63 MJPY+122.86%
-15.09 MJPY-4.98%
-15.88 MJPY-33.52%
-23.89 MJPY-86.60%
-178.27 MJPY+808.53%
-19.62 MJPY-11.91%
-22.27 MJPY-25.72%
-29.99 MJPY+49.92%
-20.00 MJPY-0.46%
-20.09 MJPY+60.88%
-12.49 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kidswell Bio Stock analysis

What does Kidswell Bio do? Kidswell Bio Corp develops biopharmaceutical products, focusing on biosimilar filgrastim and pegfilgrastim for cancer, darbepoetin alfa for renal diseases, and ranibizumab for eye diseases. The company also researches anti-RAMP2 antibodies for cancer and eye diseases, new antibodies, and regenerative medicine using intracardiac stem cells for pediatric heart conditions and dental pulp stem cells for cleft lip, palate, and intestinal ganglion cell deficiency. Revenue comes from the biosimilar business, new biopharmaceutical business, and new biotechnology business, targeting healthcare providers and medical institutions seeking cost-effective treatments. The biosimilar products include filgrastim and pegfilgrastim for cancer, darbepoetin alfa for renal diseases, and ranibizumab for eye diseases. The new biopharmaceutical business develops anti-RAMP2 antibodies and new antibodies, while the new biotechnology business focuses on regenerative medicine with stem cell applications. These products are sold to hospitals, clinics, and research institutions requiring advanced biopharmaceutical solutions. Kidswell Bio Corp's revenue streams are derived from the sale of biosimilar products, anti-RAMP2 antibodies, and regenerative medicine solutions. The company targets healthcare providers in oncology, nephrology, ophthalmology, and regenerative medicine sectors. Sales are driven by the demand for affordable alternatives to branded biologics, with a focus on pediatric and chronic disease treatments. Kidswell Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kidswell Bio stock

EBITDA per Employee of Kidswell Bio is -8.75 M JPY in 2026.

EBITDA per Employee of Kidswell Bio changed from 2.84 M JPY to -8.75 M JPY, representing a -408.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Kidswell Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Kidswell Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Kidswell Bio

All Key Metrics — Kidswell Bio